Team:Kent/teamprofile

From 2014.igem.org

(Difference between revisions)
 
(5 intermediate revisions not shown)
Line 13: Line 13:
<div class="container">
<div class="container">
-
   <div class="header"><a href="#"><img src= "https://static.igem.org/mediawiki/2014/0/04/IGEM_Header_Kent.jpg" alt="Insert Logo Here" name="Insert_logo" id="Insert_logo" width="auto" height ="107" style="background-color: #8090AB; display:block;" /></a>  
+
   <div class="header"><a href="https://2014.igem.org/Main_Page"><img src= "https://static.igem.org/mediawiki/2014/0/04/IGEM_Header_Kent.jpg" alt="Insert Logo Here" name="Insert_logo" id="Insert_logo" width="auto" height ="107" style="background-color: #8090AB; display:block;" /></a>  
     <!-- end .header --></div>
     <!-- end .header --></div>
    
    
Line 22: Line 22:
     <td><a href="https://2014.igem.org/Team:Kent/projectint"><img src="https://static.igem.org/mediawiki/2014/f/fa/Project_kent_igem2014.jpg"</a></td>
     <td><a href="https://2014.igem.org/Team:Kent/projectint"><img src="https://static.igem.org/mediawiki/2014/f/fa/Project_kent_igem2014.jpg"</a></td>
     <td><a href="https://2014.igem.org/Team:Kent/teamprofile"><img src="https://static.igem.org/mediawiki/2014/b/b9/Team_igem_kent2014.jpg"</a></td>
     <td><a href="https://2014.igem.org/Team:Kent/teamprofile"><img src="https://static.igem.org/mediawiki/2014/b/b9/Team_igem_kent2014.jpg"</a></td>
-
     <td><a href="https://2014.igem.org/Team:Kent"><img src="https://static.igem.org/mediawiki/2014/0/01/Offcial_forms_kent_2014.jpg"</a></td>
+
     <td><a href="https://2014.igem.org/Team:Kent/oficformint"><img src="https://static.igem.org/mediawiki/2014/0/01/Offcial_forms_kent_2014.jpg"</a></td>
     <td><a href="https://2014.igem.org/Team:Kent/inthuman"><img src="https://static.igem.org/mediawiki/2014/f/fb/Policey-Practices_kent_2014.jpg
     <td><a href="https://2014.igem.org/Team:Kent/inthuman"><img src="https://static.igem.org/mediawiki/2014/f/fb/Policey-Practices_kent_2014.jpg
"</a></td>
"</a></td>
Line 74: Line 74:
       <td><img src="https://static.igem.org/mediawiki/2014/1/10/Rosie-text.jpg" width="650" height="250"></td>
       <td><img src="https://static.igem.org/mediawiki/2014/1/10/Rosie-text.jpg" width="650" height="250"></td>
     </tr>
     </tr>
 +
<table width="800" border="0">
<tr>
<tr>
       <td><img src="https://static.igem.org/mediawiki/2014/2/26/Alex-alt_kent_2014.jpg" width="650" height="250"></td>
       <td><img src="https://static.igem.org/mediawiki/2014/2/26/Alex-alt_kent_2014.jpg" width="650" height="250"></td>
Line 101: Line 102:
     <tr>
     <tr>
       <td height="78" colspan="2"><p align="justify"><strong>Attributions</strong></p>
       <td height="78" colspan="2"><p align="justify"><strong>Attributions</strong></p>
-
       <p align="justify">In our Project we managed to one novel biobrick that contained the terpenoid producing enzyme R-linalool synthase. We hope that the work we have done throughout our project will help future project planning to investigate similar topics.  We would like to thank everyone above who has made this project possible, as well as our sponsors. </p></td>
+
       <p align="justify">The Kent team designed this project based on terpenoid synthase sequences reported in. We have also produced one novel biobrick that contained the terpenoid producing enzyme R-linalool synthase. We have also explored the roles and impact of Synthetic Biology in society by investigating its relationships with industry, political establishments and the general public. We engaged with British MPs by submitting a POST note about the use of Synthetic Biology to produce fragrance compounds. We developed interaction with industrial partner to devise a scale-up strategy that can be accepted by the public. Finally, we have assessed opinions of our project by collecting feedback from the public. We hope that the work we have done throughout our project will lead to future work to improve the use of synthetic biology in industry and have a positive impact on the environment. We would like to thank everyone above, the iGEM foundation, the University of Kent and our project supervisors who has made this project possible, as well as our sponsors, The University of Kent , The Biochemical Society, Society for general microbiology, Wellcome trust, BBSRC and Givaudan
 +
</p></td>
     </tr>
     </tr>
   </table>
   </table>
Line 107: Line 109:
   <p>&nbsp;</p>
   <p>&nbsp;</p>
</div>
</div>
-
<h1><!-- end .content --></h1>
+
<!-- end .content -->
 +
 
<div class="footer">
<div class="footer">
     <p>&nbsp;</p>
     <p>&nbsp;</p>

Latest revision as of 01:32, 18 October 2014

Univeristy of Kent iGEM

 

 

Instructors:

Dr Mark Shepherd
Lecturer in Microbial Biochemistry

Dr Wei-Feng Xue
Senior Lecturer in Chemical Biology


Dr Mark Wass
Lecturer in Computational Biology

Dr Gianluca Marcelli
Lecturer in Engineering

Advisors:

Morena Pappalardo

Lee Mun Ching

Ben Blakeman

Attributions

The Kent team designed this project based on terpenoid synthase sequences reported in. We have also produced one novel biobrick that contained the terpenoid producing enzyme R-linalool synthase. We have also explored the roles and impact of Synthetic Biology in society by investigating its relationships with industry, political establishments and the general public. We engaged with British MPs by submitting a POST note about the use of Synthetic Biology to produce fragrance compounds. We developed interaction with industrial partner to devise a scale-up strategy that can be accepted by the public. Finally, we have assessed opinions of our project by collecting feedback from the public. We hope that the work we have done throughout our project will lead to future work to improve the use of synthetic biology in industry and have a positive impact on the environment. We would like to thank everyone above, the iGEM foundation, the University of Kent and our project supervisors who has made this project possible, as well as our sponsors, The University of Kent , The Biochemical Society, Society for general microbiology, Wellcome trust, BBSRC and Givaudan